The Impact of Pre-Sedation Conferences on Treatment-Resistant Distress in Cancer Patients

JRCT ID: jRCT1050230148

Registered date:21/12/2023

Basic Information

• Recruitment status: Recruiting
• Health condition(s) or Problem(s) studied: Malignancy
• Date of first enrollment: 20/09/2023
• Target sample size: 250
• Study type: Observational

Outcome(s)

Primary Outcome

Primary composite endpoints
(1) Factors affecting the number of days from the start of sedation to death
(2) Patient/family satisfaction after administration of drugs for symptom relief
(3) Evaluation by medical staff after administration of drugs for symptom relief

• Secondary Outcome: Prediction of prognosis at the start of sedation and number of days from the start of sedation to death; names of drugs used for sedation and dosage (starting dose, maintenance dose, maximum dose); number of days from conference to death and drugs and dosage used (starting dose, maintenance dose, maximum dose) for cases in which symptoms were relieved with medical narcotics or other drugs without sedatives; comparison of major distress symptoms in cases in which symptom relief was possible without sedatives and those in which sedatives were necessary.

Key inclusion & exclusion criteria

• Age minimum: >= 18age old
• Age maximum: Not applicable
• Include criteria: Cancer patients and families with pre-sedation conferences between December 1, 2020 and December 31, 2025
• Exclude criteria: Pediatric (under 18 years old) cancer patients and their families

Related Information

• Primary Sponsor: Hirose Munetaka
• Source(s) of Monetary Support: Research funding from the Pain Clinic Department or the Department of Anesthesiology and Pain Control Science